ADVERTISEMENT

Uttarakhand Government Didn’t Issue Licence To Patanjali For Covid-19 Drug

Uttarakhand Ayurved Department says Patanjali was granted a licence for production of immunity booster, cough and fever medicines.

From left: Bottles of Anu Tel, Coronil and Swasari Vati—part of Patanjali Ayurved’s Divya Corona Pack touted as Covid-19 medicine. (Photo: Twitter/@yogrishiramdev)
From left: Bottles of Anu Tel, Coronil and Swasari Vati—part of Patanjali Ayurved’s Divya Corona Pack touted as Covid-19 medicine. (Photo: Twitter/@yogrishiramdev)

A day after Patanjali Ayurved Ltd. was barred from advertising or publicising its claimed ayurvedic treatment for the new coronavirus, the Uttarakhand Ayurved Department clarified that the company was granted a licence for production of immunity booster, cough and fever medicines.

Patanjali didn’t mention it was developing a drug for coronavirus while applying for the licence, according to the licence officer of Uttarakhand Ayurved Department.

The state government department will issue a notice to the yoga guru Ramdev-backed company, asking how it got permission to make the kit for Covid-19, news agency ANI said in a tweet quoting the licence officer as saying.

The Ministry of Ayush stopped Patanjali from selling and advertising its cure for the pandemic, branded ‘Coronil’, as it lacked required approvals. Facts and claims made by the company of the efficacy of its Covid-19 medicine were not known to the ministry, it said in a statement on Tuesday.

The ministry also asked the authority of Uttarakhand to provide copies of the licence and product approval details of the ayurvedic medicine.

Acharya Balkrishna, managing director at Patanjali Ayurved, however, in a tweet posted a picture of a letter it received from the Ministry of Ayush, acknowledging it has received all relevant documents of the clinical trial, including site of clinical study and medical research, study protocol, sample size and study results data. The ministry will now have to study the documents for the research outcome.

Balkrishna, late on Tuesday, tweeted saying the company has met all parameters of randomised placebo controlled clinical trials and has provided information to the Ministry of Ayush.